• Explore /
  • Poster
  • / A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) in patients with locally advanced or metastatic urothelial carcinoma.

A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) in patients with locally advanced or metastatic urothelial carcinoma.

Abstract Poster

Authors

null

Russell Kent Pachynski

Washington University School of Medicine, St. Louis, MO

Russell Kent Pachynski , Gurkamal S. Chatta , Rohit K. Jain , Helen H. Moon , Randy F. Sweis , Scott Edward Delacroix Jr., Alana Fang , Leonard A. D'amico , Angela Shaulov Kask , Steven P. Fling , Andreanne Lacroix , Judith C. Kaiser , Elad Sharon , Evan Y. Yu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03513952

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 628)

DOI

10.1200/JCO.2024.42.4_suppl.628

Abstract #

628

Poster Bd #

H13

Abstract Disclosures

Similar Posters

First Author: Evan Y. Yu

First Author: François Ghiringhelli

First Author: Maria Cortes

First Author: Deepak Kilari